ReviewCurrent atherosclerosis reports2025
Clinical Management of Dyslipidemia in Infants and Toddlers.
Review in Current atherosclerosis reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sirolimus Therapy and Dyslipidemia in Neonates and Infants: A Retrospective Cohort and Pharmacovigilance Analysis.Paediatric drugs · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewDyslipidemia can present as early as infancy however the prevalence and long-term outcomes are unclear. There is an unmet need for guidance in the evaluation and treatment approach in these patients. This review summarizes the pathophysiology of dyslipidemia in infants and toddlers and highlights potential treatment options. RECENT
findingsSecondary factors unique to this population including prematurity and reliance on intravenous nutrition play a role in the pathophysiology of dyslipidemia, though primary genetic causes are also recognized. Severe hypertriglyceridemia poses a risk of acute pancreatitis in an already vulnerable population. Persistent dyslipidemia is a concern for future premature cardiovascular disease. Management of dyslipidemia is dependent on its etiology and severity. Primary and secondary causes should be considered and addressed. Although a variety of therapeutic agents are available in older children and adults, no approved therapies exist at this age, though off-label use of medications may be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.